pharmaphorum

APRIL 5, 2022

It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes.

Labelling 52

Labelling Chemotherapy Immunization 52

pharmaphorum

OCTOBER 29, 2021

Merck is the obvious partner for that ambition as Keytruda is in the ascendency among checkpoint inhibitors for TNBC, having also recently also picked up an FDA approval pre-surgery alongside chemotherapy in the neoadjuvant setting, as well as in the post-surgery (adjuvant) setting as a monotherapy, to prevent tumours from recurring.

Chemotherapy 52

Chemotherapy FDA 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. But while companies continue studying allogeneic CAR-T therapies, including for their coveted use in solid tumours, such advancements remain challenging. But we need to recognize the challenge of solid tumours.

FDA 59

FDA Immunization 59

pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. The animal results showed dose-dependent tumour growth inhibition and efficacy beyond the treatment window, despite clearance of drug from blood and tissues.

Immunization 52

Immunization Hospitals Vaccines 52

European Pharmaceutical Review

AUGUST 24, 2022

Early dose-limiting toxicities have prohibited the expansion of ADCs into larger and more complex tumour indications, dampening the initial hopes of a new “magic bullet” in the fight against cancer. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs.

Compounding 82

Compounding Pharmaceutical Companies Pharmaceutical Companies 82

pharmaphorum

OCTOBER 4, 2022

The Biobank was launched in 2020, with an initial aim of enrolling at least 1,000 patients with locally advanced or metastatic solid tumours and haematologic malignancies undergoing standard of care therapy. Participants can also receive tumour biomarker testing that may help offer them different treatment options.

Documentation 102

Documentation Data Entry HIPAA Insurance 102

European Pharmaceutical Review

DECEMBER 27, 2023

Building on success with haematological malignancies, CAR T-cell therapy holds promise for treating solid tumours. Building on success with haematological malignancies, CAR T-cell therapy holds promise for treating solid tumours. This is in addition to its considerable price tag.

Adverse Reactions 83

Adverse Reactions Immunization Medical Schools Chemotherapy 83